London (PRWEB) November 12, 2013 -- Report Details
Prostate cancer therapeutics - assess products, developments, and revenue prospects
How are the leading segments in the prostate cancer therapeutics market performing? Visiongain's new report shows you their prospects to 2023. There you see results, trends, opportunities, and revenue predictions.
Our study lets you assess leading drugs and devices in the prostate cancer therapeutics market, showing their prospects to 2023. There you see financial results, interviews, trends, opportunities, and revenue predictions. You will also find information on pipeline drugs in the market.
Forecasts and other data to help you stay ahead
In our new study you find revenue forecasts of eight leading drugs and five device segments along with an analysis of the overall industry- with historical data, revenue forecasts, growth rates, and market shares. Discover a qualitative analysis too. You also gain 69 figures, 67 tables and an interview with an authority in the industry.
Our work lets you assess the most lucrative parts of the world market for prostate cancer therapeutic products. See now how you can benefit your research, analyses, and decisions there, also saving time.
The following sections highlight what you find in our new investigation.
Prospects for submarkets and products
In addition to analyses of the overall world market, you see revenue forecasting for the main submarkets at world level:
•Prostate cancer drugs
•Prostate cancer devices
See forecasts for prostate cancer drugs
How will drugs perform to 2023 at world level? Our study predicts individual revenues of these products:
•Zytiga
•Lupron
•Zoladex
•Casodex
•Taxotere
•Provenge
•Jevtana
•Xtandi
How will the prostate cancer devices market perform to 2023 at world level? Our study predicts individual revenues of the main devices submarkets, including these:
•The brachytherapy market
•The radical prostatectomy market
•The external beam radiation market
•The cryotherapy market
•The HIFU market
There you discover how high sales can go, to 2023.
Prospects for leading countries shown to 2023
Developments worldwide will influence the market, especially fast-rising demand in emerging countries. There will be many opportunities for prostate cancer therapies.
You discover revenue forecasts to 2023 for eleven national markets:
•US
•Japan
•Germany, France, UK, Italy, and Spain (EU5 nations)
•India
•China
•Brazil
•Russia.
This decade, revenues from India and China will be among the fastest growing worldwide.
Issues affecting the manufacturing and selling of prostate cancer therapies
In addition, our report discusses issues and events affecting that industry and market from 2013, including these:
•Drugs targeting mCRPC - driving market growth
•Strong pipeline of drugs in development
•Robotic prostatectomy - showing strong growth potential
•Prostate cancer market driven by an aging population
•Expansion internationally - targeting emerging national markets
•Stem cells - offer opportunities for growth
•High rivalry among competitors
You see discussions of technological, commercial and economic matters, with emphasis on organisations competing in the industry.
Discussions of leading companies and prospects for market growth
Our work shows you what technologies and organisations hold greatest potential. See profiles of five leading companies, including these:
•Johnson and Johnson
•AstraZeneca
•Varian Medical Systems
In general, a company profile gives you the following information
•Discussion of a company's activities and outlook
•Recent financial results
•Assessment of its developments - mergers and acquisitions (M&A), new products, and collaborations.
Discover capabilities, progress, and commercial prospects, helping you stay ahead.
Ways The Prostate Cancer Therapeutics Market 2013-2023 helps you
In summary, then, our new research and analysis give you the following knowledge:
•Revenues to 2023 for the world prostate cancer therapeutics market and its submarkets - discover that industry's prospects, finding promising places for investments and revenues
•Potential revenues of leading products to 2023
•Market forecasting to 2023 for the US, Japan, leading EU countries (Germany, France, the UK, Italy and Spain), India, China, Brazil and Russia
•Competition and opportunities - see what affects the prostate cancer therapeutics market, learning what shapes its future, esp. prospects for sustaining and developing business
•Assessment of companies - discussions of activities and outlooks
•Review of R&D pipelines by submarket - progress and trends
Information found nowhere else
That work gives independent analysis. You receive business intelligence found only in our report, seeing where prospects are most rewarding.
With our new survey you are less likely to fall behind in knowledge or miss opportunity. See there how you could benefit your research, analyses, and decisions. Also see how you can save time and get recognition for commercial insight.
1. Executive Summary
1.1 Overview of Prostate Cancer Therapeutics Market
1.2 Overview of Findings
1.3 Chapter Outline
1.4 Research and Analysis Method
1.5 Glossary of Terms Relating to Prostate Cancer Therapeutics Market
2. Introduction
2.1 What is Cancer?
2.2 Phenotypic Characteristics of Cancer Cells
2.2.1 Uncontrollable Growth
2.2.2 Loss of Apoptosis Pathways
2.2.3 Lack Differentiation
2.2.4 Increased Angiogenesis
2.2.5 Potential for Metastasis
2.2.6 Genetic Instability
2.3 What Causes Cancer?
2.4 Worldwide Prevalence of Cancer: A Global Picture
2.5 What is Prostate Cancer?
2.6 Worldwide Prevalence of Prostate Cancer: Rapid Global Growth
2.7 Risk Factors for Prostate Cancer
2.8 How is Prostate Cancer Diagnosed?
2.8.1 PSA Testing
2.8.2 Digital Rectal Examination Testing
2.8.3 Newly Approved Tests May Improve Diagnosis
2.9 Treatment Sequence for Prostate Cancer
2.9.1 Localised Prostate Cancer: Surgery/Radiation is Most Preferred
2.9.1.1 Brachytherapy
2.9.1.2 Radical Prostatectomy
2.9.1.3 External Beam Radiation Therapy
2.9.1.4 Cryotherapy
2.9.1.5 High-Intensity Focussed Ultrasound (HIFU)
2.9.2 Androgen Deprivation Therapy
2.9.3 Non-Metastatic CRPC: Ketoconazole and Anti-Androgens
2.9.4 Metastatic CRPC: Provenge Loosing its Dominance
2.9.5 First Line Chemotherapy: Docetaxel is a Standard Treatment
2.9.6 Post Docetaxel Therapy: Four FDA Approved Drugs
2.9.7 Second Line Chemotherapy: Jevtana Approved in 2010
3. The Prostate Cancer Therapeutics Market 2013-2023
3.1 The Global Prostate Cancer Therapeutics Market, 2012
3.2 The Global Prostate Cancer Therapeutics Market Forecast, 2012-2017
3.3 The Global Prostate Cancer Therapeutics Market Forecast, 2017-2023
3.4 The Global Prostate Cancer Therapeutics Market: Drivers and Restraints 2013-2023
4. The Prostate Cancer Drugs Market 2013-2023
4.1 The Prostate Cancer Drugs Market is Highly Competitive
4.2 The Prostate Cancer Drugs Market, 2012
4.3 The Prostate Cancer Drugs Market Forecast, 2012-2017
4.4 The Prostate Cancer Drugs Market Forecast, 2017-2023
4.5 Leading Prostate Cancer Drugs: Market Prospects, 2012-2023
4.5.1 Zytiga (Johnson &Johnson/Janssen)
4.5.1.1 Zytiga Sales, 2012
4.5.1.2 Zytiga Sales Forecast, 2012-2023
4.5.2 Lupron (AbbVie)
4.5.2.1 Lupron Sales, 2012
4.5.2.2 Lupron Sales Forecast, 2012-2023
4.5.3 Zoladex (AstraZeneca)
4.5.3.1 Zoladex Sales, 2012
4.5.3.2 Zoladex Sales Forecast, 2012-2023
4.5.4 Casodex (AstraZeneca)
4.5.4.1 Casodex Sales, 2012
4.5.4.2 Casodex Sales Forecast, 2012-2023
4.5.5 Taxotere (Sanofi)
4.5.5.1 Taxotere Sales, 2012
4.5.5.2 Taxotere Sales Forecast, 2012-2023
4.5.6 Provenge (Dendreon Corporation)
4.5.6.1 Provenge Sales, 2012
4.5.6.2 Provenge Sales Forecast, 2012-2023
4.5.7 Jevtana (Sanofi)
4.5.7.1 Jevtana Sales, 2012
4.5.7.2 Jevtana Sales Forecast, 2012-2023
4.5.8 Xtandi (Medivation/Astellas Pharma)
4.5.8.1 Xtandi Sales, 2012
4.5.8.2 Xtandi Sales Forecasts, 2012-2023
4.6 Late Stage Clinical Trial Failures, 2013
4.6.1 Aflibercept (Zaltrap, Regeneron/Sanofi)
4.6.2 Dasatinib (Sprycel, Bristol Myers Squibb)
4.6.3 Lenalidomide (Revlimid, Celgene)
4.6.4 TAK-700 (Orteronel, Takeda)
4.7 Prostate Cancer Drugs Pipeline, 2013
4.7.1 Yervoy (Bristol Myers Squibb)
4.7.2 Cabozantinib (Exelixis)
4.7.3 Tasquinimod (Active Biotech AB/Ipsen)
4.7.4 Prostvac (Bavarian Nordic)
4.7.5 Custirsen (OncoGenex Pharmaceuticals)
4.7.6 MDV-3100 (Medivation/Astellas Pharma)
4.7.7 ProstAtak (Advantagene)
4.7.8 DCVax-Prostate (NorthWest Biotherapeutics)
4.7.9 GVAX Prostate (Aduro Biotech)
4.7.10 GDC-0980 (Roche)
4.7.11 PSMA ADC (Progenics Pharmaceuticals)
4.7.12 EMD-525797 (EMD Sereno)
4.7.13 Galeterone (Tokai Pharmaceuticals)
4.7.14 OGX-427 (OncoGenex Pharmaceuticals)
4.7.15 ARN-509 (Johnson & Johnson)
4.7.16 MGAH22 (MacroGenics)
4.7.17 RG7450 (Roche)
4.7.18 ASG-5ME (Agensys/Seattle Genetics)
4.7.19 BAY2010112 (Bayer Pharmaceuticals)
4.7.20 GDC-0068 (Roche)
4.8 Leading Companies in the Prostate Cancer Drugs Market, 2013
4.8.1 Johnson & Johnson (J&J)
4.8.1.1 Sales and Performance Analysis, 2012
4.8.1.2 Pharmaceutical Segment Sales Analysis, 2012
4.8.1.3 Pharmaceutical Segment R&D Performance Analysis, 2012
4.8.1.4 Recent M&A Activity
4.8.1.4.1 Acquisition of Aragon Pharmaceuticals
4.8.2 AstraZeneca
4.8.2.1 Sales and Performance Analysis, 2012
4.8.2.2 R&D Performance Analysis, 2012
4.8.3 Sanofi
4.8.3.1 Sales and Performance Analysis, 2012
4.8.3.2 Oncology Sales and Performance Analysis, 2012
4.8.3.3 R&D Performance Analysis, 2012
4.8.3.4 Recent M&A Activity
5. The Prostate Cancer Devices Market 2013-2023
5.1 The Prostate Cancer Devices Market, 2012
5.2 Prostate Cancer Devices Market Forecast, 2012-2017
5.3 Prostate Cancer Devices Market Forecast, 2017-2023
5.4 Brachytherapy Market 2012-2023: Driven By Physician Adoption
5.5 Radical Prostatectomy Market 2012-2023: Higher Patient Preference
5.5.1 Intuitive Surgical's da Vinci Surgical System will Drive Market Growth
5.6 External Beam Radiation Therapy Market 2012-2023
5.7 Cryotherapy Market 2012-2023: Fastest Growing Market
5.8 HIFU Market 2012-2023: Driven by Demand for Non-Invasive Surgery
5.9 Leading Companies in the Prostate Cancer Devices Market, 2012
5.9.1 Varian Medical Systems
5.9.1.1 Sales and Performance Analysis, 2012
5.9.1.2 Oncology Systems Sales Analysis, 2012
5.9.1.3 R&D Performance Analysis, 2012
5.9.1.4 Key Oncology Products, 2013
5.9.1.5 Varian and Siemens Partnership: Shaping the Future of Cancer Care
5.9.2 Elekta
5.9.2.1 Sales and Performance Analysis, 2012
5.9.2.2 Elekta and Philips Establish Research Consortium
6. The Leading National Markets 2013-2023
6.1 Regional Breakdown of the Prostate Cancer Therapeutics Market, 2012
6.2 The Prostate Cancer Therapeutics Market: Regional Forecast 2012-2023
6.3 The US Market 2012-2023: Largest National Market
6.4 The EU5 Market 2012-2023
6.4.1 Germany and France 2012-2023: Two Largest EU Markets
6.4.2 The UK Market 2012-2023: Budgetary Constraints
6.4.3 The Spanish Market 2012-2023: Facing Cost Containment Measures
6.4.4 The Italian Market 2012-2023: Slow Growth Owing to Economic Crisis
6.5 The Japanese Market 2012-2023: Driven by Aging Population
6.6 The BRIC Nations 2012-2023: Strong Potential for Growth
6.6.1 The Chinese Market 2012-2023: Highest Revenue Generator Among BRIC Nations
6.6.2 The Indian Market 2012-2023: Lucrative Opportunity for Growth
6.6.3 The Russian Market 2012-2023: Rising Incidence of Cancer
6.6.4 The Brazilian Market 2012-2023: BRIC's Smallest Market
7. Qualitative Analysis of the Prostate Cancer Therapeutics Market 2013-2023
7.1 SWOT Analysis, 2013-2023
7.2 Strengths
7.2.1 Prostate Cancer is a High Profile Disease
7.2.2 Rapidly Expanding Aging Population
7.2.3 Strong R&D Pipeline
7.2.4 Use of Off-Label Drugs are Common
7.3 Weaknesses
7.3.1 Prostate Cancer Drugs are Expensive
7.3.2 R&D Failures in Late Stage Development
7.3.3 Impact of Economic Downturn on Healthcare Spending
7.4 Opportunities
7.4.1 Rising Incidence of Cancer
7.4.2 Emerging National Markets will Drive Growth
7.4.3 Stem Cells Offer Promise
7.4.4 Advances in Diagnostic Technologies: CTC as a Biomarker
7.5 Threats
7.5.1 Concerns about Efficacy and Toxicity of Drugs
7.5.2 Who will pay for the High Cost of Drugs and Devices?
7.5.3 Governments Cut Down Healthcare Spending
7.5.4 Increase in Generic Competition
7.6 Porter's Five Force Analysis
7.6.1 Rivalry Among Competitors
7.6.2 Threat of New Entrants
7.6.3 Power of Suppliers
7.6.4 Power of Buyers
7.6.5 Threat of Substitutes
8. Expert Opinion
8.1 Interview with Dr. Deepak Batura, Consultant Urological Surgeon
8.1.1 Views on Early-Stage Prostate Cancer Treatment
8.1.2 Advantages of Using Robots for Prostatectomy
8.1.3 Potential of HIFU to Replace Conventional Therapies
8.1.4 Does Eating Right Reduce Prostate Cancer Risk?
8.1.5 Outlook for Future
9. Conclusions
9.1 The Prostate Cancer Therapeutics Market, 2012-2023
9.2 The US Will Remain the Largest National Market during 2012-2023
9.3 Concluding Remarks
List of Tables
Table 2.1 PSA Testing: Benefits and Limitations, 2013
Table 2.2 New Prostate Cancer Diagnostic Tests in Market, 2013
Table 3.1 The Global Prostate Cancer Therapeutics Market: Revenue ($bn) and Market Shares (%) by Segment, 2012
Table 3.2 The Global Prostate Cancer Therapeutics Market Forecast: Revenue ($bn), AGR (%), CAGR (%), 2012-2017
Table 3.3 The Global Prostate Cancer Therapeutics Market Forecast: Revenue ($bn), AGR (%), CAGR (%), 2017-2023
Table 3.4 The Global Prostate Cancer Therapeutics Market: Drivers and Restraints 2013-2023
Table 4.1 The Prostate Cancer Drugs Market: Revenue ($bn) and Market Shares (%) by Leading Drugs, 2012
Table 4.2 The Prostate Cancer Drugs Market Forecast: Revenue ($bn), AGR (%), CAGR (%), 2012-2017
Table 4.3 The Prostate Cancer Drugs Market Forecast: Revenue ($bn), AGR (%), CAGR (%), 2017- 2023
Table 4.4 Zytiga: Revenue Forecast ($bn), AGR (%), CAGR (%), 2012-2023
Table 4.5 Lupron: Revenue Forecast ($bn), AGR (%) CAGR (%), 2012-2023
Table 4.6 Zoladex: Revenue Forecast ($bn), AGR (%) CAGR (%), 2012-2023
Table 4.7 Casodex: Revenue Forecast ($bn), AGR (%) CAGR (%), 2012-2023
Table 4.8 Taxotere: Revenue Forecast ($bn), AGR (%) CAGR (%), 2012-2023
Table 4.9 Provenge: Revenue Forecast ($bn), AGR (%) CAGR (%), 2012-2023
Table 4.10 Jevtana: Revenue Forecast ($bn), AGR (%) CAGR (%), 2012-2023
Table 4.11 Xtandi: Revenue Forecast ($bn), AGR (%) CAGR (%), 2012-2023
Table 4.12 Negative Phase III Trials in which Targeted Drug was Added to Docetaxel, 2013
Table 4.13 Key Drugs in Phase III Clinical Trials, 2013
Table 4.14 Key Drugs in Phase II Clinical Trials, 2013
Table 4.15 Key Drugs in Phase I Clinical Trials, 2013
Table 4.16 Johnson & Johnson: Revenue ($bn) and Revenue Shares (%) by Segment, 2012
Table 4.17 Johnson & Johnson: Pharmaceutical Revenue ($bn) and Revenue Shares (%) by Segment, 2012
Table 4.18 Johnson & Johnson: Oncology Drugs Historical Sales ($m), 2010-2012
Table 4.19 Johnson & Johnson: Historical Pharmaceutical R&D Expenses ($bn) and R&D Expenses as Percentage of Segment Revenue (%), 2010-2012
Table 4.20 AstraZeneca: Revenue ($bn) and Revenue Shares (%) by Segment, 2012
Table 4.21 AstraZeneca: Anti-Cancer Drugs Revenue ($bn), Change in Revenue (%) and Revenue Shares (%), 2011-2012
Table 4.22 Selected Drugs from AstraZeneca Oncology Pipeline, 2012
Table 4.23 Sanofi: Net Sales ($bn) and Net Sales Shares (%) by Segment, 2012
Table 4.24 Sanofi: Net Sales ($bn) and Net Sales Shares (%) by Region, 2012
Table 4.25 Sanofi: Oncology Sales ($bn) by Product, 2012
Table 4.26 Sanofi: Historical R&D Expenses ($bn) and R&D Expenses as Percentage of Revenue (%), 2010-2012
Table 5.1 The Prostate Cancer Devices Market: Revenue ($m) and Market Shares (%) by Segment, 2012
Table 5.2 The Prostate Cancer Devices Market Forecast: Revenue ($m), AGR (%), CAGR (%) by Segment, 2012-2017
Table 5.3 The Prostate Cancer Devices Market Forecast: Revenue ($m), AGR (%), CAGR (%) by Segment, 2017-2023
Table 5.4 Brachytherapy Market: Revenue Forecast ($m), AGR (%) CAGR (%), 2012-2023
Table 5.5 Radical Prostatectomy Market: Revenue Forecast ($m), AGR (%) CAGR (%), 2012-2023
Table 5.6 External Beam Radiation Therapy Market: Revenue Forecast ($m), AGR (%) CAGR (%), 2012-2023
Table 5.7 Cryotherapy Market: Revenue Forecast ($m), AGR (%) CAGR (%), 2012-2023
Table 5.8 HIFU Market: Revenue Forecast ($m), AGR (%) CAGR (%), 2012-2023
Table 5.9 Varian Medical Systems: Revenue ($bn) and Revenue Shares (%) by Segment, 2012
Table 5.10 Varian Medical Systems: Oncology Systems Revenue ($bn) and Revenue Shares (%) by Segment, 2012
Table 5.11 Varian Medical Systems: Historical R&D Expenses ($m) and R&D Expenses as Percentage of Revenue (%), 2010-2012
Table 5.12 Elekta: Net Sales ($bn) and Net Sales Shares (%) by Region, 2012
Table 6.1 The Prostate Cancer Therapeutics Market: Revenue ($bn) and Market Shares (%) by Region, 2012
Table 6.2 The Prostate Cancer Therapeutics Market Forecast: Revenue ($bn), AGR (%), CAGR (%) by Region, 2012-2017
Table 6.3 The Prostate Cancer Therapeutics Market Forecast: Revenue ($bn), AGR (%), CAGR (%) by Region, 2017-2023
Table 6.4 The US Market: Revenue Forecast ($bn), AGR (%) CAGR (%), 2012-2023
Table 6.5 The EU5 Prostate Cancer Therapeutics National Markets: Revenue ($bn) and Market Shares (%) by Country, 2012
Table 6.6 The EU5 Prostate Cancer Therapeutics Market Forecast: Revenue ($bn), AGR (%), CAGR (%) by Region, 2012-2017
Table 6.7 The EU5 Prostate Cancer Therapeutics Market Forecast: Revenue ($bn), AGR (%), CAGR (%) by Region, 2017-2023
Table 6.8 The German and French Markets: Revenue Forecast ($bn), AGR (%) CAGR (%), 2012-2023
Table 6.9 The UK Market: Revenue Forecast ($bn), AGR (%) CAGR (%), 2012-2023
Table 6.10 The Spanish Market: Revenue Forecast ($bn), AGR (%) CAGR (%), 2012-2023
Table 6.11 The Italian Market: Revenue Forecast ($bn), AGR (%) CAGR (%), 2012-2023
Table 6.12 The Japanese Market: Revenue Forecast ($bn), AGR (%) CAGR (%), 2012-2023
Table 6.13 The BRIC Prostate Cancer Therapeutics Market: Revenue ($m) and Global Market Shares (%) by Country, 2012
Table 6.14 The BRIC Prostate Cancer Therapeutics Market Forecast: Revenue ($m), AGR (%), CAGR (%) by Country, 2012-2017
Table 6.15 The BRIC Prostate Cancer Therapeutics Market Forecast: Revenue ($m), AGR (%), CAGR (%) by Country, 2017-2023
Table 6.16 The Chinese Market: Revenue Forecast ($m), AGR (%) CAGR (%), 2012-2023
Table 6.17 The Indian Market: Revenue Forecast ($m), AGR (%) CAGR (%), 2012-2023
Table 6.18 The Russian Market: Revenue Forecast ($m), AGR (%) CAGR (%), 2012-2023
Table 6.19 The Brazilian Market: Revenue Forecast ($m), AGR (%) CAGR (%), 2012-2023
Table 7.1 SWOT Analysis of the Prostate Cancer Therapeutics Market, 2013-2023
Table 9.1 Segments in the Prostate Cancer Therapeutics Market: Sales ($bn) in 2012, 2017, 2019 and 2023
Table 9.2 The Prostate Cancer Therapeutics Market by Leading Regional Markets: Sales ($bn) in 2012, 2017, 2019 and 2023
Table 9.3 Market Shares (%) of the Leading Regional Prostate Cancer Therapeutics Markets in 2012, 2017, 2019 and 2023
List of Figures
Figure 2.1 Treatment Sequence for Prostate Cancer, 2013
Figure 3.1 The Global Prostate Cancer Therapeutics Market: Revenues ($bn) by Segment, 2012
Figure 3.2 The Global Prostate Cancer Therapeutics Market: Market Shares (%) by Segment, 2012
Figure 3.3 The Global Prostate Cancer Therapeutics Market Forecast: Revenue ($bn), 2012-2017
Figure 3.4 The Global Prostate Cancer Therapeutics Market Forecast: Revenue ($bn), 2017-2023
Figure 4.1 The Prostate Cancer Drugs Market: Revenue ($bn) by Leading Drugs, 2012
Figure 4.2 The Prostate Cancer Drugs Market: Market Shares (%) by Leading Drugs, 2012
Figure 4.3 The Prostate Cancer Drugs Market Forecast: Revenue ($bn), 2012-2017
Figure 4.4 The Prostate Cancer Drugs Market Forecast: Revenue ($bn), 2017-2023
Figure 4.5 Zytiga: Revenue Forecast ($bn), 2012-2023
Figure 4.6 Lupron: Revenue Forecast ($bn), 2012-2023
Figure 4.7 Zoladex: Revenue Forecast ($bn), 2012-2023
Figure 4.8 Casodex: Revenue Forecast ($bn), 2012-2023
Figure 4.9 Taxotere: Revenue Forecast ($bn), 2012-2023
Figure 4.10 Provenge: Revenue Forecast ($bn), 2012-2023
Figure 4.11 Jevtana: Revenue Forecast ($bn), 2012-2023
Figure 4.12 Xtandi: Revenue Forecast ($bn), 2012-2023
Figure 4.13 Johnson & Johnson: Revenue Shares (%) by Segment, 2012
Figure 4.14 Johnson & Johnson: Historical Revenue ($bn), Net Income ($bn) and Profit Margin (%), 2007-2012
Figure 4.15 Johnson & Johnson: Pharmaceutical Revenue ($bn) by Segment, 2012
Figure 4.16 Johnson & Johnson: Pharmaceutical Revenue Shares (%) by Segment, 2012
Figure 4.17 Johnson & Johnson: Pharmaceutical Segment Historical Revenue ($bn) by Region, 2010-2012
Figure 4.18 Johnson & Johnson: Historical Pharmaceutical R&D Expenses ($bn) and R&D Expenses as Percentage of Segment Revenue (%), 2010-2012
Figure 4.19 AstraZeneca: Revenue ($bn) by Segment, 2012
Figure 4.20 AstraZeneca: Revenue Shares (%) by Segment, 2012
Figure 4.21 AstraZeneca: Historical R&D Expenses ($bn) and R&D Expenses as Percentage of Revenue (%), 2008-2012
Figure 4.22 Sanofi: Historical Revenue Performance ($bn), 2008-2012
Figure 4.23 Sanofi: Net Sales ($bn) by Segment, 2012
Figure 4.24 Sanofi: Net Sales Shares (%) by Segment, 2012
Figure 4.25 Sanofi: Net Sales Shares (%) by Region, 2012
Figure 4.26 Sanofi: Historical R&D Expenses ($bn) and R&D Expenses as Percentage of Revenue (%), 2010-2012
Figure 5.1 The Prostate Cancer Devices Market: Revenue ($m) by Segment, 2012
Figure 5.2 The Prostate Cancer Devices Market: Market Shares (%) by Segment, 2012
Figure 5.3 The Prostate Cancer Devices Market Forecast: Revenue ($m), 2012-2023
Figure 5.4 The Brachytherapy Market Forecast: Revenue ($m), 2012-2023
Figure 5.5 The Radical Prostatectomy Market Forecast: Revenue ($m), 2012-2023
Figure 5.6 The External Beam Radiation Therapy Market Forecast: Revenue ($m), 2012-2023
Figure 5.7 The Cryotherapy Market Forecast: Revenue ($m), 2012-2023
Figure 5.8 The HIFU Market Forecast: Revenue ($m), 2012-2023
Figure 5.9 Varian Medical Systems: Revenue ($bn) by Segment, 2012
Figure 5.10 Varian Medical Systems: Revenue Shares (%) by Segment, 2012
Figure 5.11 Varian Medical Systems: Historical Revenue ($bn), 2008-2012
Figure 5.12 Varian Medical Systems: Revenue Shares (%) by Region, 2012
Figure 5.13 Varian Medical Systems: Oncology Systems Revenue ($bn) by Segment, 2012
Figure 5.14 Varian Medical Systems: Oncology Systems Revenue Shares (%) by Segment, 2012
Figure 5.15 Varian Medical Systems: Oncology Systems Revenue Shares (%) by Region, 2012
Figure 5.16 Varian Medical Systems: Historical R&D Expenses ($m) and R&D Expenses as Percentage of Revenue (%), 2010-2012
Figure 5.17 Elekta: Historical Net Sales ($bn), 2008-2012
Figure 5.18 Elekta: Net Sales Shares (%) by Region, 2012
Figure 6.1 The Prostate Cancer Therapeutics Market: Revenue ($bn) by Region, 2012
Figure 6.2 The Prostate Cancer Therapeutics Market: Market Shares (%) by Region, 2012
Figure 6.3 The US Prostate Cancer Therapeutics Market Forecast: Revenue ($bn), 2012-2023
Figure 6.4 The EU5 Prostate Cancer Therapeutics National Markets: Revenue ($bn) by Country, 2012
Figure 6.5 The EU5 Prostate Cancer Therapeutics National Markets: Market Shares (%) by Country, 2012
Figure 6.6 The EU5 Prostate Cancer Therapeutics Market Forecast: Revenue ($bn), 2012-2023
Figure 6.7 The German and French Prostate Cancer Therapeutics Market Forecast: Revenue ($bn), 2012-2023
Figure 6.8 The UK Prostate Cancer Therapeutics Market Forecast: Revenue ($bn), 2012-2023
Figure 6.9 The Spanish Prostate Cancer Therapeutics Market Forecast: Revenue ($bn), 2012-2023
Figure 6.10 The Italian Prostate Cancer Therapeutics Market Forecast: Revenue ($bn), 2012-2023
Figure 6.11 The Japanese Prostate Cancer Therapeutics Market Forecast: Revenue ($bn), 2012-2023
Figure 6.12 The BRIC Prostate Cancer Therapeutics Market: Revenue ($m), by Country, 2012
Figure 6.13 The BRIC Prostate Cancer Therapeutics Market: Global Market Shares (%) by Country, 2012
Figure 6.14 The Chinese Prostate Cancer Therapeutics Market Forecast: Revenue ($m), 2012-2023
Figure 6.15 The Indian Prostate Cancer Therapeutics Market Forecast: Revenue ($m), 2012-2023
Figure 6.16 The Russian Prostate Cancer Therapeutics Market Forecast: Revenue ($m), 2012-2023
Figure 6.17 The Brazilian Prostate Cancer Therapeutics Market Forecast: Revenue ($m), 2012-2023
Figure 7.1 Porter's Five Force Analysis of the Prostate Cancer Therapeutics Market, 2013-2023
Figure 9.1 Prostate Cancer Therapeutics Market: Sales ($bn) in 2012, 2017, 2019 and 2023
Figure 9.2 The Prostate Cancer Therapeutics Market: Market Shares (%) by Region, 2023
Companies Listed
AbbVie
Accord Healthcare
Actavis, Inc.
Active Biotech AB
Aduro Biotech
Advanced Medical Isotope Corporation
Advantagene, Inc.
Agensys
American Cancer Society
Amgen
Antoni Van Leeuwenhoek Hospital
Aragon Pharmaceuticals
Astellas Pharma
AstraZeneca
Bavarian Nordic
Bayer HealthCare
Beckman Coulter, Inc.
Bellicum Pharmaceuticals, Inc.
BioSante Pharmaceuticals
Bostwick Laboratories
Bristol Myers Squibb
BTG plc
C.R. Bard, Inc.
Calypso
Cancer Research UK
Cedars-Sinai Medical Centre
Celgene Corporation
Committee for Medicare and Medicaid Services
Computer Motion
Cougar Biotechnology
Dendreon Corporation
Dosch Pharmaceuticals Pvt Ltd
Ealing Hospital NHS Trust
EDAP TMS
Elekta
EMD Serono
European Association of Urology
European Medicines Agency (EMA)
European Partnership Action Against Cancer (EPAAC)
Exelixis
Food and Drug Administration (FDA)
Genentech (Roche)
Genfar Laboratories
GenomeDX Biosciences
Genomic Health, Inc.
Genzyme
GLOBOCAN
Hologic, Inc.
Hospira Inc
Intuitive Surgical
Ipsen
Iris International
Italian National Health Service
Johnson & Johnson
Levine Cancer Institute
MacroGenics
MDxHealth
Medical College of Wisconsin
Medivation
Metabolon, Inc.
Metamark Genetics
Micromet (Amgen)
Mitomics, Inc.
Mylan Pharmaceuticals, Inc.
Myriad Genetics
National Cancer Institute (NCI)
National Epidemiological Centre
National Health Service (NHS)
National Institute of Clinical Excellence (NICE)
Newport Laboratories
NorthWest Biotherapeutics
Nucletron
OncoGenex Pharmaceuticals
Oncura, Inc.
Opko Health, Inc.
Philips
Pluromed, Inc.
Princess Margaret Cancer Center
Progenics Pharmaceuticals, Inc.
Radon Ltd
Regeneron Pharmaceuticals, Inc.
Roche
Sandoz
Sanofi
Seattle Genetics
Siemens
SonaCare Medical
Sun Pharmaceuticals Ltd
Sunnybrook Health Sciences Centre
Synthon Pharmaceuticals, Inc.
Takeda Pharmaceutical Co Ltd
Teva
The Clinical Cancer Center at Froedtert
The Netherlands Cancer Institute
The University of Texas MS Anderson Centre
Tokai Pharmaceuticals, Inc.
United Nations (UN)
University Medical Centre Utrecht
University of California
University of York
Varian Medical Systems
World Health Organisation
YCR Cancer Research
Zydus Pharmaceuticals
Read the full report:
The Prostate Cancer Therapeutics Market 2013-2023
For more information:
Sarah Smith
Research Advisor at Reportbuyer.com
Email: [email protected]
Tel: +44 208 816 85 48
Website: http://www.reportbuyer.com
Sarah Smith, Research Advisor at Reportbuyer.com, +44 208 816 85 48, [email protected]
Share this article